Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 6
1962 9
1963 4
1964 8
1965 10
1966 9
1967 6
1968 11
1969 9
1970 11
1971 5
1972 11
1973 9
1974 12
1975 17
1976 14
1977 12
1978 17
1979 16
1980 25
1981 27
1982 31
1983 39
1984 34
1985 30
1986 43
1987 51
1988 43
1989 50
1990 49
1991 58
1992 51
1993 49
1994 66
1995 87
1996 79
1997 71
1998 80
1999 90
2000 77
2001 82
2002 88
2003 78
2004 83
2005 87
2006 104
2007 92
2008 81
2009 96
2010 87
2011 111
2012 96
2013 96
2014 91
2015 87
2016 97
2017 85
2018 115
2019 134
2020 153
2021 178
2022 174
2023 138
2024 146

Text availability

Article attribute

Article type

Publication date

Search Results

3,573 results

Results by year

Filters applied: . Clear all
Page 1
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Saji H, et al. Among authors: fukuda h. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. Lancet. 2022. PMID: 35461558 Clinical Trial.
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Aokage K, et al. Among authors: fukuda h. Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6. Lancet Respir Med. 2023. PMID: 36893780 Clinical Trial.
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). Ozaka M, et al. Among authors: fukuda h. Eur J Cancer. 2023 Mar;181:135-144. doi: 10.1016/j.ejca.2022.12.014. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36652891 Free article. Clinical Trial.
A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study).
Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S, Sakanaka K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Takeuchi H, et al. Among authors: fukuda h. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):454-462. doi: 10.1016/j.ijrobp.2022.07.007. Epub 2022 Aug 4. Int J Radiat Oncol Biol Phys. 2022. PMID: 35932949
Peptide Signaling Pathways in Vascular Differentiation.
Fukuda H, Hardtke CS. Fukuda H, et al. Plant Physiol. 2020 Apr;182(4):1636-1644. doi: 10.1104/pp.19.01259. Epub 2019 Dec 3. Plant Physiol. 2020. PMID: 31796560 Free PMC article. Review.
Repeat conformation heterogeneity in cerebellar ataxia, neuropathy, vestibular areflexia syndrome.
Miyatake S, Yoshida K, Koshimizu E, Doi H, Yamada M, Miyaji Y, Ueda N, Tsuyuzaki J, Kodaira M, Onoue H, Taguri M, Imamura S, Fukuda H, Hamanaka K, Fujita A, Satoh M, Miyama T, Watanabe N, Kurita Y, Okubo M, Tanaka K, Kishida H, Koyano S, Takahashi T, Ono Y, Higashida K, Yoshikura N, Ogata K, Kato R, Tsuchida N, Uchiyama Y, Miyake N, Shimohata T, Tanaka F, Mizuguchi T, Matsumoto N. Miyatake S, et al. Among authors: fukuda h. Brain. 2022 Apr 29;145(3):1139-1150. doi: 10.1093/brain/awab363. Brain. 2022. PMID: 35355059
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Maruyama T, Kuwabara K, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Fukuda H, et al. Cancer Sci. 2024 Jun;115(6):1763-1777. doi: 10.1111/cas.16154. Epub 2024 Mar 25. Cancer Sci. 2024. PMID: 38527308 Free PMC article.
3,573 results